{
    "Trade/Device Name(s)": [
        "Borrelia B31 IgM ViraStripe\u00ae"
    ],
    "Submitter Information": "ViraLab Biotech, AG",
    "510(k) Number": "K082329",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "August 5, 2009",
    "Summary Letter Received Date": "July 30, 2009",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema pallidum treponemal test reagents"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "IgM antibodies against Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Line blot assay"
    ],
    "Methodologies": [
        "Qualitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Borrelia B31 IgM ViraStripe\u00ae, an in vitro qualitative assay for detection of IgM antibodies against Borrelia burgdorferi in human serum.",
    "Indications for Use Summary": "Qualitative detection of IgM antibodies against Borrelia burgdorferi in human serum as supportive evidence of Lyme disease infection in patients with positive or equivocal EIA or IFA test results.",
    "fda_folder": "Microbiology"
}